Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma
Source: MedPageToday , August 2023
Combined BRAF-MEK inhibition for advanced BRAF-mutant melanoma led to significantly better progression-free survival (PFS) as compared with single-agent BRAF inhibition, according to a randomized trial.
Patients who received encorafenib (Braftovi) plus binimetinib (Mektovi) had a median PFS of 12.9 months as compared with 9.2 and 7.4 months for two cohorts treated with encorafenib alone. The outcome added to previously reported results
opens in a new tab or window
that demonstrated the combination’s superiority versus single-agent vemurafenib (Zelboraf) and a numerical advantage compared with single-agent encorafenib.
The combination was better tolerated and associated with a higher relative dose intensity versus encorafenib alone, reported Paolo A. Ascierto, MD, of Istituto Nazionale dei Tumori in Naples, Italy, and co-authors in the Journal of Clinical Oncology
opens in a new tab or window
.